BFM
AKBA icon

Boothbay Fund Management’s Akebia Therapeutics AKBA Stock Holding History

Boothbay Fund Management’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-240,000
Closed -$439K – 1489
2024
Q1 		$439K Buy
+240,000
New +$384K 0.01% 1051
2022
Q2 		– Sell
-392,300
Closed -$282K – 2215
2022
Q1 		$282K Buy
+392,300
New +$839K 0.01% 1651

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

Boothbay Fund Management's AKBA Position: Q2 2022 in Review

Boothbay Fund Management sold out of Akebia Therapeutics (AKBA) in Q2 2022, closing a stake of 246,300 shares — an estimated $177K sold.

Boothbay Fund Management first reported a position in AKBA in Q4 2018 and held it in 10 quarters. The position peaked at $852K in Q1 2019. 96 funds tracked by Wall St. Rank hold AKBA as of Q2 2022.

  • Boothbay Fund Management reported no remaining Akebia Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Boothbay Fund Management sold 246,300 Akebia Therapeutics shares in Q2 2022, an estimated $177K.
  • Boothbay Fund Management first reported a position in Akebia Therapeutics in Q4 2018 and held it in 10 quarters.
  • Boothbay Fund Management's Akebia Therapeutics position peaked at $852K in Q1 2019.
  • 96 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2022.

Based on Boothbay Fund Management's 13F filing for Q2 2022, filed 15 Aug 2022.